Compugen to Present at the Cowen and Company 39th Annual Health Care Conference

Tuesday, March 5, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

HOLON, Israel, March 5, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development

of first-in-class therapeutics for cancer immunotherapy, today announced that John Hunter, PhD, Chief Scientific Officer, will present a corporate overview and update at the Cowen and Company 39th Annual Health
Care Conference in Boston, on Monday, March 11, 2018, at 2:50 PM.

A live webcast of the presentation will be available on Compugen's website. A replay will be available after the presentation ends.

About Compugen

Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with facilities in both Israel and South San Francisco, CA. Compugen's shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.

Company contact:Elana HolzmanDirector, Investor Relations and Corporate CommunicationsCompugen Ltd.Email: elanah@cgen.comTel: +972(3)765-8124

Investor Relations contact:Burns McClellan, Inc.Jill SteierEmail: jsteier@burnsmc.com Tel: 212-213-0006

Cision View original content:http://www.prnewswire.com/news-releases/compugen-to-present-at-the-cowen-and-company-39th-annual-health-care-conference-300806583.html

SOURCE Compugen Ltd.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store